A genome-wide association study (GWAS) published in Frontiers in Oncology has identified a specific genetic variant in the MAVS gene associated with an increased risk of Kaposi sarcoma (KS) in people living with HIV. This research provides the first evidence of inherited germline susceptibility to the cancer in children and highlights the RIG-I/MAVS signaling pathway as a potential driver of disease development.
Genetic Links to Kaposi Sarcoma Susceptibility
Kaposi sarcoma is a vascular tumor triggered by human herpesvirus-8 (HHV-8) infection, particularly in individuals with compromised immune systems. While HIV and HHV-8 are primary drivers, clinical observation has long suggested that not every patient with these factors develops the malignancy. According to the study by McAtee et al. (2026), inherited genetic variation may account for these differences in susceptibility.
The research team identified a missense variant, rs7269320, in the mitochondrial antiviral-signalling (MAVS) gene. In the discovery cohort of 45 children with HIV and KS, this variant showed a strong association with the disease, with an odds ratio of 3.8. Researchers subsequently validated these findings in an independent cohort of 215 adults living with HIV and KS, where the variant demonstrated a recessive inheritance pattern with an odds ratio of 2.2.
Did you know?
The RIG-I/MAVS pathway is a critical component of the body’s innate immune system. When this pathway is dysfunctional, the body struggles to mount an effective antiviral cytokine response against HHV-8, which can lead to viral reactivation and increase the risk of oncogenesis.
Biological Pathways and Future Clinical Implications
The identification of the MAVS variant offers a clearer picture of how host genetics interact with viral pathogens. Because the MAVS protein is essential for detecting viral threats, its deficiency or dysfunction effectively lowers the biological barrier to HHV-8-driven cancer. By pinpointing this specific pathway, researchers have established a new framework for understanding why some patients are more vulnerable than others.
Future applications of this discovery could include:
- Risk Stratification: Identifying high-risk individuals in clinical settings based on their genetic profile.
- Targeted Therapeutics: Developing novel treatments that aim to stabilize or restore the RIG-I/MAVS signaling pathway.
The investigators note that while these findings are significant, they require further replication and functional studies to fully map the biological mechanism. Determining how exactly the rs7269320 variant influences disease risk remains the next hurdle for researchers in the field of oncology and infectious disease.
Frequently Asked Questions
What is the role of the MAVS gene in Kaposi sarcoma?
The MAVS gene is part of the RIG-I/MAVS signaling pathway, which helps the immune system respond to viruses. Dysfunction in this gene can impair the body’s ability to control HHV-8, the virus that causes Kaposi sarcoma, potentially allowing the cancer to develop.
Is this genetic risk factor only relevant for children?
No. While this study provided the first evidence of germline susceptibility in children, the findings were also replicated in an adult cohort living with HIV, suggesting the variant plays a role in susceptibility across different age groups.
How was this association discovered?
Researchers used a genome-wide association study (GWAS) to analyze single-nucleotide variants across the genomes of 45 children with HIV and KS, followed by a validation study in 215 adults with the same conditions.
Pro Tip:
For clinicians managing patients with HIV, understanding the intersection of viral load and host genetics is becoming increasingly important. Keep an eye on emerging genomic screening tools that may soon help personalize monitoring for patients at high risk of KS.
To stay updated on the latest developments in HIV research and oncology, subscribe to our newsletter or explore our archive of clinical studies. Have a question about these findings? Share your thoughts in the comments section below.
Worth a look